Mesoblast Limited announced the retirement of two board members, William Burns after 12 years and Dr. Philip Krause since 2022, recognizing their significant contributions. The company, now a revenue-generating commercial enterprise following the FDA approval and launch of its cell therapy Ryoncil, plans to recruit new directors with global commercial expertise in biotechnology and pharmaceuticals to support its next growth phase. This move aligns with Mesoblast's focus on expanding its commercial operations and developing additional cell therapies for inflammatory diseases.
Following the board changes at Mesoblast Limited, the company's stock is currently trading at USD 15.16 on Pluang as of Nov 02, 2026 07:01 WIB, down 3.25% for the day. The market values Mesoblast at $2.06 billion, with the share price fluctuating between a 52-week low of $11.95 and a high of $20.96. Investors typically hold this stock for about 16 days on the platform.
